Of a large cohort of CLL patient tumor samples characterized using short-read RNA-Seq17, we present the resequencing of a subset of these transcriptomes, globally, with nanopore technology: three with wild-type SF3B1, three with the K700E mutation, and three additional normal B-cell samples, which are the normal lineage cellular complement to CLL, to use as a normal tissue control42. The gene discussed is SF3B1; the disease is B-cell chronic lymphocytic leukemia.